Consensus PROCEPT BioRobotics Corporation

Equities

PRCT

US74276L1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
61.74 ^USD	+1.86%		+17.64%	+47.32%

May. 02	Truist Raises PROCEPT BioRobotics' PT to $72 From $63 After 'Solid' Q1 Beat, Keeps Buy Rating	MT
May. 01	Procept BioRobotics Shares Rise After Q1 Loss Narrows, Revenue Increases; 2024 Revenue Guidance Revised	MT

Evolution of the average Target Price on PROCEPT BioRobotics Corporation

Price target over the last 5 years

History of analyst recommendation changes

4383b9fbf6f2.y9UQMRagbZV-thmUDgnSLEzonMMw58mK8_m9zz6TtsE.vbR4Y0_nFP4a5X3-SluQGj6s67dKla3upJfprkvl5LLyhmleTuEU0xzvTA~276e5b57f6e302c559ec1b5f37c9848d

Analyst Recommendations on PROCEPT BioRobotics Corporation

Truist Raises PROCEPT BioRobotics' PT to $72 From $63 After 'Solid' Q1 Beat, Keeps Buy Rating	May. 02	MT
Procept Biorobotics Insider Sold Shares Worth $263,243, According to a Recent SEC Filing	Mar. 21	MT
Wells Fargo Adjusts Price Target on PROCEPT BioRobotics to $47 From $44, Maintains Overweight Rating	Jan. 09	MT
Truist Securities Raises Price Target on PROCEPT BioRobotics to $50 From $48, Maintains Buy Rating	Dec. 22	MT
Wells Fargo Raises Price Target on PROCEPT BioRobotics to $44 From $40, Maintains Overweight Rating	Dec. 13	MT
B. Riley Lowers PROCEPT BioRobotics' PT to $55 From $60 on Lower Multiple, Keeps Buy Rating	Nov. 02	MT
Piper Sandler Initiates PROCEPT BioRobotics at Overweight With $42 Price Target	23-08-11	MT
William Blair Initiates PROCEPT BioRobotics at Outperform Rating	23-05-31	MT
Truist Adjusts Price Target on PROCEPT BioRobotics to $49 From $54, Keeps Buy Rating	23-05-01	MT
KeyBanc Adjusts Price Target on PROCEPT BioRobotics to $47 From $48, Maintains Overweight Rating	23-05-01	MT
BofA Securities Adjusts PROCEPT BioRobotics' Price Target to $44 From $52, Keeps Buy Rating	23-04-28	MT
Truist Adjusts PROCEPT BioRobotics' Price Target to $49 From $54, Keeps Buy Rating	23-04-28	MT
Truist Securities Trims Price Target on PROCEPT BioRobotics to $55 From $58, Maintains Buy Rating	23-01-31	MT
Wells Fargo Adjusts Price Target on PROCEPT BioRobotics to $43 From $52, Maintains Overweight Rating	23-01-12	MT
Wells Fargo Adjusts Price Target on PROCEPT BioRobotics to $52 From $49, Maintains Overweight Rating	22-12-12	MT
Truist Securities Adjusts PROCEPT BioRobotics Price Target to $58 From $56, Maintains Buy Rating	22-11-14	MT
KeyBanc Capital Markets Adjusts Price Target on PROCEPT BioRobotics to $48 From $47, Maintains Overweight Rating	22-11-04	MT
B. Riley Raises PROCEPT BioRobotics' Price Target to $60 From $53, Keeps Buy Rating	22-11-04	MT
BTIG Starts PROCEPT BioRobotics at Neutral	22-10-31	MT
Truist Securities Starts PROCEPT BioRobotics at Buy With $58 Price Target	22-10-25	MT
Wells Fargo Starts PROCEPT BioRobotics at Overweight With $49 Price Target	22-09-02	MT
Goldman Sachs Adjusts Price Target for PROCEPT BioRobotics to $39 From $36, Maintains Neutral Rating	22-08-05	MT
KeyBanc Starts PROCEPT BioRobotics at Overweight With $47 Price Target	22-07-15	MT
B. Riley Initiates PROCEPT BioRobotics at Buy with $53 PT, Says Set to Outperform SMID-Cap MedTech Peers as Adoption of Aquablation Robotic Technology Ramps	22-06-23	MT
Guggenheim Adjusts PROCEPT BioRobotics' Price Target to $40 from $55, Maintains Buy Rating	22-03-09	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

61.74 USD

Average target price

60.83 USD

Spread / Average Target

-1.47%

High Price Target

67 USD

Spread / Highest target

+8.52%

Low Price Target

55 USD

Spread / Lowest Target

-10.92%

Consensus detail

Consensus revision (last 18 months)

Analysts covering PROCEPT BioRobotics Corporation

Wells Fargo Securities
Truist Securities
B. Riley
Piper Sandler
William Blair & Co.
KeyBanc Capital Markets
BofA Securities
BTIG
Goldman Sachs
SVB Leerink
Guggenheim
Cowen

Ratings for PROCEPT BioRobotics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar